精神醫學的共同研究及授權契約:2019年～2025年

《精神病學合作與許可交易》提供了前所未有的途徑，可以全面了解全球領先的生物製藥公司正在進行的精神病學交易。

這份經過全面修訂和更新的報告提供了 2019 年至 2025 年 569 項精神病學交易的詳細資訊。

此報告提供雙方宣布的交易付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判交易條款的彈性可以為談判過程提供重要的見解，讓您了解談判條款時會發生什麼。許多小型企業可能會想要詳細的付款條款，但當涉及到如何產生付款以及如何轉移權利時，細節決定成敗。

本報告提供了當前協議交易和合作資料庫中記錄的自 2019 年以來宣布的合作和許可協議的綜合列表，包括可用的財務條款，並包含公司及其合作夥伴向 SEC 提交的實際許可協議文件的在線副本鏈接。

本報告的第一部分描述了精神病學領域的貿易和商業活動。第 1 章對報告進行了介紹，第 2 章分析了精神病學領域的交易趨勢。

第 3 章介紹精神醫學領域已達成交易的財務條款以及發展階段公告。交易按標題價值、預付款、里程碑付款和特許費率列出並分為幾個部分。

第 4 章回顧了精神病領域交易最活躍的 25 家生物製藥公司。對於美國證券交易委員會已公開宣布協議的案件，可以透過這些連結在當前協議交易和聯盟資料庫中線上存取該協議。

第 5 章對 2016 年以來簽署和宣布的精神病學交易進行了全面深入的回顧，並提供合約文件。每個交易標題都透過網路連結連結到實際合約文件的線上版本，從而可以根據需要輕鬆存取每個文件。

第六章提供了按治療目標分類的精神病病例的綜合目錄。

它也提供了大量圖表和圖形，展示了 2019 年及以後的精神病學交易趨勢和活動。

此外，我們還提供按公司 A-Z 和技術類型組織的綜合貿易目錄。每個交易標題都提供了一個指向在線交易記錄的網絡鏈接，並在可用的情況下提供合同文件，從而允許根據需要輕鬆訪問每個文件。

主要優點

精神醫學合作研究和授權協議為讀者提供了以下主要好處：

• 了解 2019 年及以後的合約趨勢
• 查看精神科合作研究和許可機會
• 基準分析 - 確定交易的市場價值
• 財務條款 – 預付款、里程碑付款、特許權使用費
• 依公司 A-Z、治療目標、技術類型劃分的交易目錄
• 大額交易金額
• 最活躍的交易者
• 確定每筆交易的資產和條款
• 查閱合約文件－洞察交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性。
• 節省數百小時的研究時間

研究範圍

• 精神病學研究合作與許可協議旨在從全球領先的生物製藥公司更深入地了解精神病學趨勢和交易結構。

回報內容

• 生物製藥產業精神醫學領域的趨勢
• 合作與授權交易結構概述
• 涵蓋製藥和生物技術的精神病學交易記錄目錄
• 重大精神醫學交易
• 最活躍的精神科許可公司

目錄

摘要整理

第1章 簡介

第2章 精神醫學的交易趨勢

• 簡介
• 長期的精神科合作關係
• 以交易類型劃分的精神科合作關係
• 精神醫學與產業界的合作（依領域）
• 根據發展階段進行精神醫學合作
• 按技術類型劃分的精神科合作
• 基於治療指徵的精神科合作

第3章 精神醫學的聯盟的金錢的交易條件

• 簡介
• 揭露精神醫學合作的財務條款
• 精神科夥伴關係的核心價值
• 精神醫學中的前期交易
• 精神醫學交易中的里程碑付款
• 精神病專利費率

第4章 精神醫學主要的交易和交易負責人

• 簡介
• 精神科合作領域最活躍的公司
• 精神科領域最活躍的交易者名單
• 以價值為排名的頂級精神科交易

第5章 精神醫學的契約文件名錄

• 簡介
• 已簽約的精神科聯盟契約

第6章 按治療標的精神醫學的交易

• 簡介
• 按精神科治療標的交易
• 交易名錄
• 交易目錄 - 2019 年至 2025 年精神科交易（依公司劃分）
• 交易目錄 - 按技術類型劃分的精神病學交易（2019-2025 年）
• 定義交易類型
• 關於 Biopharma Research Ltd
• 當前合作夥伴關係
• 當前合約
• Current Partnering 的最新報告標題

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse psychiatry collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

• Trends in psychiatry dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of psychiatry deal records covering pharmaceutical and biotechnology
• The leading psychiatry deals by value
• Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

• 2.1. Introduction
• 2.2. Psychiatry partnering over the years
• 2.3. Psychiatry partnering by deal type
• 2.4. Psychiatry partnering by industry sector
• 2.5. Psychiatry partnering by stage of development
• 2.6. Psychiatry partnering by technology type
• 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for psychiatry partnering
• 3.3. Psychiatry partnering headline values
• 3.4. Psychiatry deal upfront payments
• 3.5. Psychiatry deal milestone payments
• 3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in psychiatry partnering
• 4.3. List of most active dealmakers in psychiatry
• 4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

• 5.1. Introduction
• 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by psychiatry therapeutic target
• Deal directory
• Deal directory - Psychiatry deals by company A-Z 2019 to 2025
• Deal directory - Psychiatry deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Psychiatry partnering since 2019
• Figure 2: Psychiatry partnering by deal type since 2019
• Figure 3: Psychiatry partnering by industry sector since 2019
• Figure 4: Psychiatry partnering by stage of development since 2019
• Figure 5: Psychiatry partnering by technology type since 2019
• Figure 6: Psychiatry partnering by indication since 2019
• Figure 7: Psychiatry deals with a headline value
• Figure 8: Psychiatry deals with upfront payment values
• Figure 9: Psychiatry deals with milestone payment
• Figure 10: Psychiatry deals with royalty rates
• Figure 11: Active psychiatry dealmaking activity since 2019
• Figure 12: Top psychiatry deals by value since 2019